-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Genmab, Raises Price Target to $42

Benzinga·08/07/2026 16:59:17
Listen to the news
Guggenheim analyst Michael Schmidt maintains Genmab (NASDAQ:GMAB) with a Buy and raises the price target from $40 to $42.